SERA PROGNOSTICS REPORTS THIRD QUARTER 2026 FINANCIAL RESULTS
PR Newswire•04/11/2026•16:05 ET
0
Key Highlights
- ➤PreTRM test volume rose 54% sequentially and nearly five-fold from 1Q26
- ➤Third-quarter PreTRM revenue reached $42,000, up 163% year over year
- ➤Florida Medicaid coverage added approximately 4 million beneficiaries and 90,000 annual births
- ➤Cash, equivalents and marketable securities totaled $72.8 million; quarterly operating cash burn was $7.3 million
- ➤Net loss widened to $8.053 million, or $0.16 per share, from $7.814 million
Expert Statements
Zhenya Lindgardt, President and Chief Executive Officer of Sera Prognostics
“The third quarter marked an important step forward as we continued our transition from evidence generation to commercial execution”
Zhenya Lindgardt, President and Chief Executive Officer of Sera Prognostics
“We delivered strong growth in physician adoption and test volume, saw expanded reimbursement through a second state Medicaid coverage win in Florida, advanced our commercial payer initiatives, and continued to strengthen our clinical and health economic evidence base.”
Zhenya Lindgardt, President and Chief Executive Officer of Sera Prognostics
“Furthermore, following strong supporting evidence, we are working with our notified body to submit our CE Mark for our kit-based PreTRM® Global test.”
Zhenya Lindgardt, President and Chief Executive Officer of Sera Prognostics
“We believe these accomplishments further validate our strategy and position us well as we work toward establishing PreTRM as a foundational component of prenatal care.”
SERA PROGNOSTICS REPORTS THIRD QUARTER 2026 FINANCIAL RESULTS PR Newswire
Company Drives Significant Increases in Test Volume and Ordering Providers with Florida Becoming Second Medicaid State Covering Test
Get started
Create a free account to read the full story.